Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer

Phase II Clinical Trial

A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer
Trial Number: 06369285
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations